What does ETABLISSEMENT LA TRANSFUSION DU SANG do?

ETABLISSEMENT LA TRANSFUSION DU SANG is a healthcare practice in Charleroi. Non-profit, started on 17 September 1935, 1 establishment.

What is the address of ETABLISSEMENT LA TRANSFUSION DU SANG?

The registered office of ETABLISSEMENT LA TRANSFUSION DU SANG is located at Boulevard Joseph II 11B, 6000 Charleroi.

Is ETABLISSEMENT LA TRANSFUSION DU SANG still active?

Yes. According to the CBE (22 September 2026) ETABLISSEMENT LA TRANSFUSION DU SANG is active, legal situation “Normale toestand”, started on 17 September 1935.

Is ETABLISSEMENT LA TRANSFUSION DU SANG registered on Peppol?

Yes, ETABLISSEMENT LA TRANSFUSION DU SANG is registered on the Peppol network with ID 0208:0401574357.

What is the enterprise number of ETABLISSEMENT LA TRANSFUSION DU SANG?

The enterprise number of ETABLISSEMENT LA TRANSFUSION DU SANG is BE0401574357.

When was ETABLISSEMENT LA TRANSFUSION DU SANG founded?

ETABLISSEMENT LA TRANSFUSION DU SANG was founded on 17 September 1935.

Who are the directors of ETABLISSEMENT LA TRANSFUSION DU SANG?

According to the 2025 annual accounts, the directors of ETABLISSEMENT LA TRANSFUSION DU SANG are: Jacques MAIRESSE, Benjamin KERZMANN, Jérémie GRAS, Caroline MEGALI, Patrick VANKERKHOVEN, Stéphane EECKHOUDT, Frédéric FLAMAND, Nabil DAOUDI.

Is ETABLISSEMENT LA TRANSFUSION DU SANG a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 September 1935; 5 annual accounts filed, latest fiscal year 2025; 10 directors known from the annual account.

How much profit did ETABLISSEMENT LA TRANSFUSION DU SANG make in 2025?

ETABLISSEMENT LA TRANSFUSION DU SANG recorded a loss after taxes of € 114,590 in financial year 2025.

What is the revenue of ETABLISSEMENT LA TRANSFUSION DU SANG?

In its most recent annual accounts (2025), ETABLISSEMENT LA TRANSFUSION DU SANG reported revenue of € 4,813,091.

How much does an employee at ETABLISSEMENT LA TRANSFUSION DU SANG earn?

The average wage cost per full-time employee at ETABLISSEMENT LA TRANSFUSION DU SANG was € 79,700 in 2025: staff costs of € 2.6 million for 32.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ETABLISSEMENT LA TRANSFUSION DU SANG have?

According to the 2025 annual accounts, ETABLISSEMENT LA TRANSFUSION DU SANG has 32.5 full-time equivalents (FTE).

Does ETABLISSEMENT LA TRANSFUSION DU SANG have a website?

Yes, ETABLISSEMENT LA TRANSFUSION DU SANG has a website at dondesang.be.

ETABLISSEMENT LA TRANSFUSION DU SANG (Non-profit)

Dossier ETABLISSEMENT LA TRANSFUSION DU SANG, printed on 22 September 2026 from databakkes.be/en/0401574357/etablissement-la-transfusion-du-sang. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

ETABLISSEMENT LA TRANSFUSION DU SANG from Charleroi, company number BE0401574357, closed financial year 2025 with a result of € -114,590 after tax. For that financial year ETABLISSEMENT LA TRANSFUSION DU SANG recorded revenue of € 4.8 million and equity of € 2.5 million. Compared with financial year 2024, the result moved from € -448,489 to € -114,590. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 4, 2026.

What it is worth Healthy

€ 2.5 million

▼ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -114,590

▲ 74 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 506,646

▼ 22% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Full-time equivalents

32.5

▼ 1.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 2.6 million

▼ 4% vs 2024

€ 79,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 122,846

▼ 9% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 399,046

▼ 36% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 388,735

▼ 7% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 5,156,301 Revenue 2022: € 5,156,301 First fiscal year in the series	€ 4,823,492 Revenue 2023: € 4,823,492 ▼ 6% vs 2022 (€ 5,156,301) Unfavourable step	€ 4,558,264 Revenue 2024: € 4,558,264 ▼ 5% vs 2023 (€ 4,823,492) Unfavourable step	€ 4,813,091 Revenue 2025: € 4,813,091 ▲ 6% vs 2024 (€ 4,558,264) Favourable step	▲ 6%
Gross margin	€ 2,301,874 Gross margin 2022: € 2,301,874 First fiscal year in the series	€ 2,287,988 Gross margin 2023: € 2,287,988 ▼ 1% vs 2022 (€ 2,301,874) Unfavourable step	€ 2,316,778 Gross margin 2024: € 2,316,778 ▲ 1% vs 2023 (€ 2,287,988) Favourable step	€ 2,577,948 Gross margin 2025: € 2,577,948 ▲ 11% vs 2024 (€ 2,316,778) Favourable step	▲ 11%
Profit after taxes	€ -55,867 Profit after taxes 2022: € -55,867 First fiscal year in the series	€ -305,342 Profit after taxes 2023: € -305,342 ▼ € 249,475 vs 2022 (€ -55,867) Unfavourable step	€ -448,489 Profit after taxes 2024: € -448,489 ▼ € 143,147 vs 2023 (€ -305,342) Unfavourable step	€ -114,590 Profit after taxes 2025: € -114,590 ▲ € 333,899 vs 2024 (€ -448,489) Favourable step	▲ € 333,899
Equity	€ 3,359,921 Equity 2022: € 3,359,921 First fiscal year in the series	€ 3,054,579 Equity 2023: € 3,054,579 ▼ 9% vs 2022 (€ 3,359,921) Unfavourable step	€ 2,606,090 Equity 2024: € 2,606,090 ▼ 15% vs 2023 (€ 3,054,579) Unfavourable step	€ 2,491,500 Equity 2025: € 2,491,500 ▼ 4% vs 2024 (€ 2,606,090) Unfavourable step	▼ 4%
Total debts	€ 882,302 Total debts 2022: € 882,302 First fiscal year in the series	€ 810,857 Total debts 2023: € 810,857 ▼ 8% vs 2022 (€ 882,302) Favourable step	€ 1,044,780 Total debts 2024: € 1,044,780 ▲ 29% vs 2023 (€ 810,857) Unfavourable step	€ 791,857 Total debts 2025: € 791,857 ▼ 24% vs 2024 (€ 1,044,780) Favourable step	▼ 24%
Cash	€ 1,853,084 Cash 2022: € 1,853,084 First fiscal year in the series	€ 574,726 Cash 2023: € 574,726 ▼ 69% vs 2022 (€ 1,853,084) Unfavourable step	€ 650,795 Cash 2024: € 650,795 ▲ 13% vs 2023 (€ 574,726) Favourable step	€ 506,646 Cash 2025: € 506,646 ▼ 22% vs 2024 (€ 650,795) Unfavourable step	▼ 22%
Land & buildings	€ 218,550 Land & buildings 2022: € 218,550 First fiscal year in the series	€ 214,578 Land & buildings 2023: € 214,578 ▼ 2% vs 2022 (€ 218,550) Unchanged	€ 210,701 Land & buildings 2024: € 210,701 ▼ 2% vs 2023 (€ 214,578) Unchanged	€ 210,734 Land & buildings 2025: € 210,734 Unchanged (€ 210,701) Unchanged
Retained profit	€ 1,954,921 Retained profit 2022: € 1,954,921 First fiscal year in the series	€ 1,649,579 Retained profit 2023: € 1,649,579 ▼ 16% vs 2022 (€ 1,954,921) Unfavourable step	€ 1,201,090 Retained profit 2024: € 1,201,090 ▼ 27% vs 2023 (€ 1,649,579) Unfavourable step	€ 1,086,500 Retained profit 2025: € 1,086,500 ▼ 10% vs 2024 (€ 1,201,090) Unfavourable step	▼ 10%
Balance sheet total	€ 4,242,223 Balance sheet total 2022: € 4,242,223 First fiscal year in the series	€ 3,865,436 Balance sheet total 2023: € 3,865,436 ▼ 9% vs 2022 (€ 4,242,223) Unchanged	€ 3,650,870 Balance sheet total 2024: € 3,650,870 ▼ 6% vs 2023 (€ 3,865,436) Unchanged	€ 3,283,357 Balance sheet total 2025: € 3,283,357 ▼ 10% vs 2024 (€ 3,650,870) Unchanged	▼ 10%
Employees (FTE)	32.5 Employees (FTE) 2022: 32.5 First fiscal year in the series	35.2 Employees (FTE) 2023: 35.2 ▲ 2.7 vs 2022 (32.5) Unchanged	34.2 Employees (FTE) 2024: 34.2 ▼ 1 vs 2023 (35.2) Unchanged	32.5 Employees (FTE) 2025: 32.5 ▼ 1.7 vs 2024 (34.2) Unchanged	▼ 1.7

Key figures of ETABLISSEMENT LA TRANSFUSION DU SANG, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ETABLISSEMENT LA TRANSFUSION DU SANG?

What happened at ETABLISSEMENT LA TRANSFUSION DU SANG in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Jérémie GRAS stepped down as director. NBB
2028 Frédéric FLAMAND stepped down as director. NBB
2028 Manfredi VENTURA stepped down as director. NBB
2027 Benjamin KERZMANN stepped down as director. NBB
2027 Caroline MEGALI stepped down as director. NBB
2027 Patrick VANKERKHOVEN stepped down as director. NBB
2027 Stéphane EECKHOUDT stepped down as director. NBB
2027 Nabil DAOUDI stepped down as director. NBB

In short

From € 55,867 loss in 2022 to € 114,590 loss in 2025.

Paid € 18,576 in corporate taxes since 2022.

On average € 79,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at ETABLISSEMENT LA TRANSFUSION DU SANG? We notify you, reason included.

Follow ETABLISSEMENT LA TRANSFUSION DU SANG

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Directors

According to the 2025 annual accounts

Jacques MAIRESSE

Chairman of the board

since 2022 · until 2027

Benjamin KERZMANN

Director

since 2022 · until 2027

Jérémie GRAS

Director

Also active at: Société de Biologie Médicale et Moléculaire JM Gras

since 2024 · until 2029

Caroline MEGALI

Director

since 2022 · until 2027

Patrick VANKERKHOVEN

Director

since 2022 · until 2027

Stéphane EECKHOUDT

Director

since 2022 · until 2027

Frédéric FLAMAND

Director

Also active at: INSTITUT DE PATHOLOGIE ET DE GENETIQUE, ProtonW.be

since 2023 · until 2028

Nabil DAOUDI

Director

since 2022 · until 2027

Manfredi VENTURA

Vice-chairman of the board

since 2023 · until 2028

Valérie SELOSSE

Director

Also active at: BIOPATH.MED

since 2022 · until 2027

Establishments

Establishment units

Physical locations of this company

Registered office

Boulevard Joseph II 11B

6000 Charleroi

2.155.440.364

Boulevard Joseph II 11 B

6000 Charleroi

Active since 17 September 1935

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS dondesang.be

Technologies

ApacheGoogle Tag ManagerPWA

Hosting & Email

Email provider

Microsoft 365

Hosting

OVH, FR

Website info

HTTPS Ja

Languages FR

Features

Ads

Security

✓ HTTPS

✓ SPF

✗ DMARC

Details

Company number

0401.574.357

VAT number

BE 0401.574.357

Registered office

Boulevard Joseph II 11B, 6000 Charleroi

Names & denominations

ETABLISSEMENT LA TRANSFUSION DU SANG · Don de Sang

Enterprise type

Rechtspersoon

Legal form

Non-profit association

Legal situation

Normale toestand

Start date

17 September 1935

Peppol

Active · Active since 1 Dec 2025

Contact

dondesang.be [email protected]

Activities · NACE

Activiteiten van bloedtransfusiecentra, bloedbanken, spermabanken, organenbanken en dergelijke

Activiteiten van bloedtransfusiecentra en bloed- en organenbanken

View on CBE Public ↗ Annual accounts (NBB) ↗

ETABLISSEMENT LA TRANSFUSION DU SANG

Warning lights

Financials

What happened to ETABLISSEMENT LA TRANSFUSION DU SANG?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions